^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLH1 mutation

    i
    Other names: MLH1, COCA2, FCC2, HNPCC, HNPCC2, MutL homolog 1
    Entrez ID:
    4292
    Related biomarkers:
    Mutation
    CNA
    Others
    Apply
    Researching the Effect of Aerobic Exercise on Cancer (NCT03996239)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/20/2019
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Atorvastatin ± Aspirin in Lynch Syndrome Syndrome (NCT04379999)
    Phase 1
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    09/10/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MLH1 • MSH6 • MSH2 • EPCAM • CASP3
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    atorvastatin
    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    10/16/2017
    Primary completion :
    04/02/2025
    Completion :
    04/02/2025
    MLH1 • MSH6 • MSH2 • CD4
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation • MSH6 expression
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    Pancreatic Cancer Early Detection Program (PCEDP) (NCT02206360)
    Phase N/A
    White Plains Hospital
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2024
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Nivolumab in Biochemically Recurrent dMMR Prostate Cancer (NCT04019964)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    01/13/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    TMB • MSI • MLH1 • MSH6 • MSH2 • CDK12
    |
    MSI-H/dMMR • CDK12 mutation • MSH2 mutation • MLH1 mutation
    |
    Opdivo (nivolumab)
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (NCT05078866)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    11/10/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    NOUS-209
    Pancreatic Cancer Screening for At-risk Individuals (PancreasScan) (NCT05006131)
    Phase N/A
    Beth Israel Deaconess Medical Center
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/10/2020
    Primary completion :
    03/10/2027
    Completion :
    03/10/2028
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
    A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome (NCT05411718)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/21/2023
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    aspirin
    GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study (NCT03751761)
    Phase 1/2
    Asan Medical Center
    Completed
    Last update posted :
    02/28/2024
    Initiation :
    06/11/2018
    Primary completion :
    08/30/2023
    Completion :
    08/30/2023
    PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation
    |
    Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab)
    Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis (NCT06206083)
    Phase N/A
    National Institute of Cancerología
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    03/01/2024
    Primary completion :
    11/01/2026
    Completion :
    02/01/2027
    TP53 • MSI • POLE • MLH1 • MSH6 • MSH2
    |
    POLE mutation • MLH1 mutation
    Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes (NCT02371135)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/02/2024
    Initiation :
    02/01/2015
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study (NCT05410977)
    Phase N/A
    Mayo Clinic
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    03/30/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/17/2024
    Initiation :
    04/18/2017
    Primary completion :
    04/18/2024
    Completion :
    04/18/2024
    ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRIP1 mutation • MSH2 mutation • RAD51C mutation • MLH1 mutation • RAD51D mutation • PMS2 mutation • BARD1 mutation • RAD51 mutation
    Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome (NCT03495674)
    Phase N/A
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/05/2024
    Initiation :
    04/04/2018
    Primary completion :
    01/02/2024
    Completion :
    01/02/2024
    MSI • MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer (NCT05013216)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    09/04/2023
    Initiation :
    04/11/2022
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1
    |
    KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation
    |
    Hiltonol (poly-ICLC) • KRAS peptide vaccine
    CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome (CADLYNCH) (NCT05963191)
    Phase N/A
    PERROD Guillaume
    Not yet recruiting
    Last update posted :
    07/27/2023
    Initiation :
    10/02/2023
    Primary completion :
    10/02/2023
    Completion :
    10/02/2025
    MSH2
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) (NCT03434158)
    Phase 2
    Spanish Oncology Genito-Urinary Group
    Completed
    Last update posted :
    11/03/2022
    Initiation :
    02/06/2018
    Primary completion :
    05/12/2022
    Completion :
    05/12/2022
    BRCA1 • BRCA2 • HRD • MLH1 • MSH6 • MSH2 • CHEK2 • RAD51C
    |
    CHEK2 mutation • MLH1 mutation
    |
    Lynparza (olaparib) • docetaxel
    Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (MesaCAPP) (NCT04920149)
    Phase 2
    Ann-Sofie Backman
    Recruiting
    Last update posted :
    03/28/2022
    Initiation :
    03/21/2022
    Primary completion :
    10/15/2028
    Completion :
    10/15/2038
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation
    the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer (NCT05131243)
    Phase N/A
    Fujian Cancer Hospital
    Not yet recruiting
    Last update posted :
    11/23/2021
    Initiation :
    12/01/2021
    Primary completion :
    05/01/2023
    Completion :
    05/01/2023
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation
    Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome (NCT02052908)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    01/25/2021
    Initiation :
    01/27/2014
    Primary completion :
    10/25/2019
    Completion :
    01/05/2021
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MLH1 mutation • PMS2 mutation
    Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy (NCT03631641)
    Phase 2
    Joanne Jeter
    Unknown status
    Last update posted :
    05/15/2020
    Initiation :
    08/21/2018
    Primary completion :
    12/31/2020
    Completion :
    12/31/2020
    MLH1 • MSH2
    |
    MSH2 mutation • MLH1 mutation
    |
    Opdivo (nivolumab)
    Naproxen for Lynch Syndrome (NCT02048735)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    12/12/2017
    Initiation :
    01/01/2014
    Primary completion :
    01/01/2021
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Prostate Cancer Screening Among Men With High Risk Genetic Predisposition (NCT02053805)
    Phase N/A
    Rabin Medical Center
    Unknown status
    Last update posted :
    10/17/2017
    Initiation :
    02/01/2014
    Primary completion :
    06/01/2018
    Completion :
    06/01/2019
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
    The GEOLynch Cohort Study (NCT03303833)
    Phase N/A
    Wageningen University
    Recruiting
    Last update posted :
    10/06/2017
    Initiation :
    07/01/2006
    Primary completion :
    12/01/2030
    Completion :
    12/01/2030
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (NCT02864979)
    Phase 2
    Rabin Medical Center
    Not yet recruiting
    Last update posted :
    09/20/2017
    Initiation :
    08/01/2016
    Primary completion :
    07/01/2022
    Completion :
    07/01/2022
    MLH1 • MSH6 • MSH2
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer (NCT00341575)
    Phase N/A
    National Human Genome Research Institute (NHGRI)
    Completed
    Last update posted :
    07/02/2017
    Initiation :
    09/28/2005
    Completion :
    08/02/2010
    MSH2
    |
    MSH2 mutation • MLH1 mutation
    Cancer Genetics Hereditary Cancer Panel Testing (NCT02324062)
    Phase N/A
    University of Southern California
    Completed
    Last update posted :
    04/11/2017
    Initiation :
    06/12/2014
    Primary completion :
    01/05/2017
    Completion :
    01/05/2017
    PTEN • MLH1 • MSH6 • MSH2 • BRCA
    |
    MSH6 mutation • MLH1 mutation
    Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome (ChromoLynch) (NCT00905710)
    Phase N/A
    University Medical Center Groningen
    Completed
    Last update posted :
    05/13/2016
    Initiation :
    09/01/2008
    Primary completion :
    05/01/2016
    Completion :
    05/01/2016
    MLH1 • MSH6 • MSH2
    |
    MSH6 mutation • MSH2 mutation • MLH1 mutation
    Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome (CELSIUS) (NCT00898768)
    Phase 1
    University Medical Center Groningen
    Completed
    Last update posted :
    12/09/2014
    Initiation :
    05/01/2009
    Primary completion :
    12/01/2014
    Completion :
    12/01/2014
    MLH1 • MSH6 • MSH2
    |
    MSH2 mutation • MLH1 mutation